iRadimed (IRMD) Competitors $66.17 +7.83 (+13.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$66.05 -0.12 (-0.18%) As of 08/1/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRMD vs. WRBY, LIVN, EYE, LMAT, LQDA, CNMD, ENOV, SSII, CDRE, and NVCRShould you be buying iRadimed stock or one of its competitors? The main competitors of iRadimed include Warby Parker (WRBY), LivaNova (LIVN), National Vision (EYE), LeMaitre Vascular (LMAT), Liquidia Technologies (LQDA), CONMED (CNMD), Enovis (ENOV), SS Innovations International (SSII), Cadre (CDRE), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry. iRadimed vs. Its Competitors Warby Parker LivaNova National Vision LeMaitre Vascular Liquidia Technologies CONMED Enovis SS Innovations International Cadre NovoCure iRadimed (NASDAQ:IRMD) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Does the media prefer IRMD or WRBY? In the previous week, iRadimed had 3 more articles in the media than Warby Parker. MarketBeat recorded 17 mentions for iRadimed and 14 mentions for Warby Parker. Warby Parker's average media sentiment score of 1.06 beat iRadimed's score of 0.50 indicating that Warby Parker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Warby Parker 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IRMD or WRBY more profitable? iRadimed has a net margin of 26.33% compared to Warby Parker's net margin of -1.79%. iRadimed's return on equity of 23.28% beat Warby Parker's return on equity.Company Net Margins Return on Equity Return on Assets iRadimed26.33% 23.28% 20.59% Warby Parker -1.79%-2.48%-1.29% Do analysts recommend IRMD or WRBY? iRadimed currently has a consensus target price of $72.00, suggesting a potential upside of 8.81%. Warby Parker has a consensus target price of $23.13, suggesting a potential downside of 2.05%. Given iRadimed's stronger consensus rating and higher possible upside, equities research analysts clearly believe iRadimed is more favorable than Warby Parker.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRadimed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Warby Parker 0 Sell rating(s) 9 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53 Do insiders & institutionals hold more shares of IRMD or WRBY? 92.3% of iRadimed shares are owned by institutional investors. Comparatively, 93.2% of Warby Parker shares are owned by institutional investors. 36.8% of iRadimed shares are owned by company insiders. Comparatively, 18.2% of Warby Parker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, IRMD or WRBY? iRadimed has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Warby Parker has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Which has higher earnings & valuation, IRMD or WRBY? iRadimed has higher earnings, but lower revenue than Warby Parker. Warby Parker is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiRadimed$73.24M11.49$19.23M$1.5542.69Warby Parker$771.32M3.20-$20.39M-$0.12-196.75 SummaryiRadimed beats Warby Parker on 11 of the 16 factors compared between the two stocks. Get iRadimed News Delivered to You Automatically Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRMD vs. The Competition Export to ExcelMetriciRadimedMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$741.80M$6.76B$5.49B$9.52BDividend Yield1.17%1.32%4.73%4.09%P/E Ratio42.6920.9428.7823.81Price / Sales11.4954.12372.2066.04Price / Cash36.8720.5035.4557.96Price / Book9.664.468.275.54Net Income$19.23M$174.54M$3.25B$259.28M7 Day Performance17.49%-5.27%-3.70%-4.64%1 Month Performance7.52%-3.94%4.34%4.41%1 Year Performance49.03%8.26%25.90%17.95% iRadimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRMDiRadimed4.1846 of 5 stars$66.17+13.4%$72.00+8.8%+43.4%$741.80M$73.24M42.69110Trending NewsDividend AnnouncementGap UpHigh Trading VolumeWRBYWarby Parker2.0999 of 5 stars$24.10-1.2%$22.88-5.1%+48.9%$2.55B$771.32M-200.833,780News CoveragePositive NewsUpcoming EarningsAnalyst ForecastShort Interest ↑LIVNLivaNova2.9776 of 5 stars$43.46-0.5%$59.29+36.4%-14.9%$2.38B$1.25B-10.632,900News CoveragePositive NewsUpcoming EarningsEYENational Vision2.8888 of 5 stars$24.48-2.2%$23.00-6.0%+78.3%$1.98B$1.82B-74.1813,411Positive NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionLMATLeMaitre Vascular2.9929 of 5 stars$82.47+0.0%$97.83+18.6%-6.0%$1.86B$219.86M41.65490Upcoming EarningsLQDALiquidia Technologies3.3973 of 5 stars$19.82+1.1%$26.89+35.7%+52.5%$1.68B$14M-12.5450News CoverageUpcoming EarningsCNMDCONMED4.4135 of 5 stars$50.05-1.8%$62.20+24.3%-20.0%$1.58B$1.32B13.173,900News CoverageEarnings ReportAnalyst ForecastENOVEnovis2.9614 of 5 stars$27.36-0.7%$55.60+103.2%-44.7%$1.57B$2.11B-1.967,367Upcoming EarningsSSIISS Innovations InternationalN/A$7.20+0.3%N/AN/A$1.39B$20.65M0.004CDRECadre3.1541 of 5 stars$33.60-0.9%$37.50+11.6%-9.5%$1.38B$567.56M35.372,284Upcoming EarningsNVCRNovoCure4.4172 of 5 stars$11.64-3.3%$28.79+147.3%-47.1%$1.34B$605.22M-7.461,488News CoverageInsider Trade Related Companies and Tools Related Companies WRBY Competitors LIVN Competitors EYE Competitors LMAT Competitors LQDA Competitors CNMD Competitors ENOV Competitors SSII Competitors CDRE Competitors NVCR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRMD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRadimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share iRadimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
